The Therapeutic Goods Administration has given the go ahead to a game-changing new treatment, marking a major step forward in ...
A new treatment for early to mild Alzheimer’s disease has been registered with Australia’s pharmaceutical regulator, the ...
TipRanks on MSN
Biogen, Eisai announces TGA of Australia approved LEQEMBI
Eisai and Biogen (BIIB) announced that the Therapeutic Goods Administration, TGA,of Australia has approved the humanized anti ...
LEQEMBI is a monoclonal antibody that is administered in a specialised centre via a one-hour intravenous infusion every two weeks and targets the underlying pathology of Alzheimer's disease. 1,2 ...
On 23 September 2025 the TGA made the decision to approve the registration of the lecanemab (LEQEMBI).What is LEQEMBI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback